PMID- 31788081
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 18
IP  - 6
DP  - 2019 Dec
TI  - Prognostic genes of melanoma identified by weighted gene co-expression network 
      analysis and drug repositioning using a network-based method.
PG  - 6066-6078
LID - 10.3892/ol.2019.10961 [doi]
AB  - Melanoma is one of the most malignant types of skin cancer. However, the efficacy 
      and utility of available drug therapies for melanoma are limited. The objective 
      of the present study was to identify potential genes associated with melanoma 
      progression and to explore approved therapeutic drugs that target these genes. 
      Weighted gene co-expression network analysis was used to construct a gene 
      co-expression network, explore the associations between genes and clinical 
      characteristics and identify potential biomarkers. Gene expression profiles of 
      the GSE65904 dataset were obtained from the Gene Expression Omnibus database. 
      RNA-sequencing data and clinical information associated with melanoma obtained 
      from The Cancer Genome Atlas were used for biomarker validation. A total of 15 
      modules were identified through average linkage hierarchical clustering. In the 
      two significant modules, three network hub genes associated with melanoma 
      prognosis were identified: C-X-C motif chemokine receptor 4 (CXCR4), interleukin 
      7 receptor (IL7R) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
      subunit gamma (PIK3CG). The receiver operating characteristic curve indicated that 
      the mRNA levels of these genes exhibited excellent prognostic efficiency for 
      primary and metastatic tumor tissues. In addition, the proximity between 
      candidate genes associated with melanoma progression and drug targets obtained 
      from DrugBank was calculated in the protein interaction network, and the top 15 
      drugs that may be suitable for treating melanoma were identified. In summary, 
      co-expression network analysis led to the selection of CXCR4, IL7R and PIK3CG for 
      further basic and clinical research on melanoma. Utilizing a network-based 
      method, 15 drugs that exhibited potential for the treatment of melanoma were 
      identified.
CI  - Copyright: (c) Wang et al.
FAU - Wang, Lu
AU  - Wang L
AD  - Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, P.R. China.
FAU - Wei, Chuan-Yuan
AU  - Wei CY
AD  - Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, P.R. China.
FAU - Xu, Yuan-Yuan
AU  - Xu YY
AD  - Department of Surgery, The First Hospital of Shanxi Medical University, Taiyuan, 
      Shanxi 030001, P.R. China.
FAU - Deng, Xin-Yi
AU  - Deng XY
AD  - Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, P.R. China.
FAU - Wang, Qiang
AU  - Wang Q
AD  - Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, P.R. China.
FAU - Ying, Jiang-Hui
AU  - Ying JH
AD  - Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, P.R. China.
FAU - Zhang, Si-Min
AU  - Zhang SM
AD  - Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, P.R. China.
FAU - Yuan, Xin
AU  - Yuan X
AD  - Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, P.R. China.
FAU - Xuan, Tian-Fan
AU  - Xuan TF
AD  - Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, P.R. China.
FAU - Pan, Yu-Yan
AU  - Pan YY
AD  - Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, P.R. China.
FAU - Gu, Jian-Ying
AU  - Gu JY
AD  - Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20191004
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6864934
OTO - NOTNLM
OT  - drug repositioning
OT  - melanoma
OT  - prognosis
EDAT- 2019/12/04 06:00
MHDA- 2019/12/04 06:01
PMCR- 2019/10/04
CRDT- 2019/12/03 06:00
PHST- 2019/02/12 00:00 [received]
PHST- 2019/08/21 00:00 [accepted]
PHST- 2019/12/03 06:00 [entrez]
PHST- 2019/12/04 06:00 [pubmed]
PHST- 2019/12/04 06:01 [medline]
PHST- 2019/10/04 00:00 [pmc-release]
AID - OL-0-0-10961 [pii]
AID - 10.3892/ol.2019.10961 [doi]
PST - ppublish
SO  - Oncol Lett. 2019 Dec;18(6):6066-6078. doi: 10.3892/ol.2019.10961. Epub 2019 Oct 
      4.